Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CytRx has commenced a pharmacokinetic clinical trial with its oncology drug candidate Bafetinib, where six to eight patients with recurrent primary brain cancer or recurrent brain metastases, who have undergone brain surgery, will be evaluated.
Subscribe to our email newsletter
The results from this trial are expected in the second quarter of 2011 and will be used in evaluating potential further clinical development of Bafetinib in patients with brain cancer.
The trial’s primary objective is to provide neuropharmacokinetic information, such as the ability of Bafetinib to cross the blood:brain barrier and the percentage that enters the brain compared to the amount in systemic blood.
CytRx chief medical officer Daniel Levitt said that this clinical trial is designed to provide proof of Bafetinib’s ability to cross the blood:brain barrier, verifying results from prior animal studies.
"This trial also will allow us to gain initial experience in terms of Bafetinib’s tolerability at the dose under consideration for possible future testing in patients with brain cancer," Levitt said.